Keyword Analysis & Research: pazopanib pk

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
pazopanib pk0.550.188825212
pazopanib1.4216319209
pk0.951972552

Keyword Research: People who searched pazopanib pk also searched

Keyword CPC PCC Volume Score
pazopanib pk0.80.5816645

Search Results related to pazopanib pk on Search Engine

  • Pazopanib Exposure Relationship with Clinical Efficacy …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/34577627/

    WEBJul 1, 2018 · Population PK analysis. The pazopanib population PK model was previously developed with historical PK data including 451 subjects (healthy volunteers and cancer … Author: Cora N. Sternberg, Frede Donskov, Naomi B. Haas, Christian Doehn, Paul Russo, Mohamed Elmeliegy, Gui... Publish Year: 2018 Published: 2018/07/07

    Author: Cora N. Sternberg, Frede Donskov, Naomi B. Haas, Christian Doehn, Paul Russo, Mohamed Elmeliegy, Gui...

    Publish Year: 2018

    Published: 2018/07/07

    DA: 64 PA: 6 MOZ Rank: 92

  • Clinical Pharmacokinetics and Pharmacodynamics of …

    drugbank.com

    https://go.drugbank.com/drugs/DB06589

    WEBFeb 10, 2017 · Pazopanib is a synthetic 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide and is part of the group of indazolyl … Author: Remy B. Verheijen, Jos H. Beijnen, Jos H. Beijnen, Jan H. M. Schellens, Jan H. M. Schellens, Alwin D... DOI: 10.1007/s40262-017-0510-z Publish Year: 2017 Publication: Clin Pharmacokinet. 2017; 56(9): 987-997.

    Author: Remy B. Verheijen, Jos H. Beijnen, Jos H. Beijnen, Jan H. M. Schellens, Jan H. M. Schellens, Alwin D...

    DOI: 10.1007/s40262-017-0510-z

    Publish Year: 2017

    Publication: Clin Pharmacokinet. 2017; 56(9): 987-997.

    DA: 51 PA: 60 MOZ Rank: 24

  • Pazopanib Exposure Relationship with Clinical Efficacy and Safety in th…

    aacrjournals.org

    https://aacrjournals.org/clincancerres/article/24/13/3005/80962/Pazopanib-Exposure-Relationship-with-Clinical

    DA: 8 PA: 22 MOZ Rank: 16

  • Therapeutic drug monitoring of pazopanib: Using cost-neutral PK …

    ascopubs.org

    https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3598

    WEBMay 25, 2020 · Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure. Stefanie L. Groenland. , Ruben A.G. van Eerden. , … Author: Stefanie L. Groenland, Ruben A.G. van Eerden, Stijn L.W. Koolen, Dirk Jan A.R. Moes, Alex Imholz, So... Publish Year: 2020

    Author: Stefanie L. Groenland, Ruben A.G. van Eerden, Stijn L.W. Koolen, Dirk Jan A.R. Moes, Alex Imholz, So...

    Publish Year: 2020

    DA: 62 PA: 51 MOZ Rank: 64

  • Pazopanib Exposure Relationship with Clinical Efficacy and …

    aacrjournals.org

    https://aacrjournals.org/clincancerres/article/24/13/3005/80962/Pazopanib-Exposure-Relationship-with-Clinical

    WEBJul 1, 2018 · Pazopanib pharmacokinetic (PK) data were analyzed via a population model approach. Relationship between C trough or dose intensity and disease-free survival …

    DA: 13 PA: 99 MOZ Rank: 49

  • Pazopanib Exposure Relationship with Clinical Efficacy …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/29330204/

    WEBJul 1, 2018 · Pazopanib pharmacokinetic (PK) data were analyzed via a population model approach. Relationship between C trough or dose intensity and disease-free survival …

    DA: 98 PA: 59 MOZ Rank: 97

  • CENTER FOR DRUG EVALUATION AND …

    fda.gov

    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf

    WEBPazopanib is an ATP-competitive, second-generation inhibitor of tyrosine kinase activity associated with human VEGFR-1, -2 and -3, and platelet-derived growth factor receptor …

    DA: 96 PA: 87 MOZ Rank: 5

  • Prediction for optimal dosage of pazopanib under various …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/36172188/

    WEBSep 12, 2022 · This study aimed to apply a physiologically based pharmacokinetic (PBPK) model to predict optimal dosing regimens of pazopanib (PAZ) for safe and effective …

    DA: 99 PA: 57 MOZ Rank: 76

  • Pharmacokinetically guided dosing has the potential to improve …

    wiley.com

    https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14580

    WEBOct 3, 2020 · We also sought to characterize the clinical PK of pazopanib and investigate the potential impacts of pharmacogenetics as well as gastric acid-suppressive (GAS) …

    DA: 63 PA: 56 MOZ Rank: 22